Details for New Drug Application (NDA): 074654
✉ Email this page to a colleague
NDA 074654 describes ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, which is a drug marketed by Sandoz and Stevens J and is included in two NDAs. Additional details are available on the ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE profile page.
The generic ingredient in ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is aspirin; caffeine; orphenadrine citrate. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.
The generic ingredient in ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is aspirin; caffeine; orphenadrine citrate. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.
Summary for 074654
| Tradename: | ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE |
| Applicant: | Sandoz |
| Ingredient: | aspirin; caffeine; orphenadrine citrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 385MG;30MG;25MG | ||||
| Approval Date: | Dec 31, 1996 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 770MG;60MG;50MG | ||||
| Approval Date: | Dec 31, 1996 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
